Malaysia has become the prefered choice for Clinigen Group a global pharmaceutical company with operations in Europe, Australia and Japan as the group opens its new office in Kuala Lumpur.
Clinigen which is involved in clinical trial medicines and uniquely positioned as a global distributor, is strategising to expand its footprint in Southeast Asia via the Malaysian base.
The Group’s strategy in Malaysia is to become the vendor of choice for the sourcing and supply of medicines to its customers, providing additional infrastructure to support its mission to deliver the right medicine to the right patient and the right time. In a statement, the group highlighted its immediate aim is to expand access to unlicensed medicines by extending the reach of the Group’s Unlicensed Medicines exclusive supply agreements and on-demand service, as well as offering clinical services to its customers.
On a longer term strategy, Clinigen’s presence will increase its capability in the supply and distribution of products from the Group’s portfolio of licensed medicines and makes it a more attractive partner for pharma companies looking to commercialise their products outside of their home geographies, using the groups regulatory expertise.
Shaun Chilton Group CEO, “Pharmaceutical and biotechnology companies are increasingly looking for specialist partners to work with them in Asia. The opening of our Malaysian office provides Clinigen with greater opportunities to offer our customers at both a global and local level.”
Clinigen employs over 1,150 people globally, across 14 international locations. The opening of the Malaysian office further expands its international supply chain and operational network.